Vedere Bio II · 重建方案

Leverage AI and machine learning to enhance the development of gene therapies for vision restoration. By integrating AI, the company could significantly reduce the time and cost of pre-clinical research, modeling potential outcomes and optimizing experimental designs.

Today, the biotech industry continues to advance with notable breakthroughs in gene therapy and regenerative medicine. Companies like Novartis and Roche are leading the charge in vision restoration, utilizing advancements in CRISPR and other gene-editing technologies. An AI-native rebuild in this space could focus on accelerating the discovery phases using machine learning to predict therapeutic outcomes or optimize gene-editing techniques.

1. Step 1: AI-first prototype blueprint to model retinal responses to gene therapy.

2. Step 2: Distribution/Validation strategy by partnering with leading ophthalmology research centers.

3. Step 3: Growth loop by establishing a platform for collaborative research and data sharing.

4. Step 4: Moat strategy by developing proprietary AI models optimized for optogenetic applications.

• OpenAI
• TensorFlow
• AWS
• CRISPR editing tools

Monetization could involve licensing AI-driven research tools to biotech firms, offering subscription-based access to predictive models for therapy outcomes, and forming strategic partnerships with pharmaceutical companies for co-development of therapies.